Vital Signs The Analyst's Perspective - October 2016 Issue

Vital Signs The Analyst's Perspective - October 2016 Issue

RELEASE DATE
02-Nov-2016
REGION
Global
Research Code: 9A35-00-4F-00-00
SKU: HC02724-GL-MR_19422

$600.00

Special Price $450.00 save 25 %

In stock
SKU
HC02724-GL-MR_19422

$600.00

$450.00 save 25 %

DownloadLink

Pay by invoice

ENQUIRE NOW

Description

This Vital Signs issue discusses the Danaher's acquisition of Cepheid for nearly $4 Billion in cash, and Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007–2013.

Table of Contents

Related Research
This Vital Signs issue discusses the Danaher's acquisition of Cepheid for nearly $4 Billion in cash, and Orphan Drug Expenditures in the United States: A Historical and Prospective Analysis, 2007–2013.
More Information
No Index No
Podcast No
Author Christi Bird
WIP Number 9A35-00-4F-00-00
Is Prebook No